Printer Friendly

PHYTON CATALYTIC AND BRISTOL-MYERS SQUIBB EXPAND ON PRODUCTION OF PACLITAXEL (TAXOL(R)) FROM PLANT CELL CULTURES

 ITHACA, N.Y., Aug. 3 /PRNewswire/ -- Phyton Catalytic, Inc. today announced that it has signed an expanded Strategic Development Collaboration (SDC) agreement with Bristol-Myers Squibb Company to continue exploring the feasibility of large-scale production of paclitaxel using Phyton Catalytic's proprietary plant cell culture technology. Paclitaxel is the active drug substance in Bristol-Myers Squibb's anti-cancer drug TAXOL(R).
 Phyton Catalytic first entered into a collaborative research and development contract with Bristol-Myers Squibb in September 1991 to test the feasibility of producing paclitaxel on a commercial scale from its plant cell culture process. The companies established the new agreement following successful completion of the objectives of the initial contract. The new multi-year, multi-million dollar agreement provides for financial support to paclitaxel process research and development.
 TAXOL was approved by the U.S. Food and Drug Administration in December 1992 for the treatment of ovarian cancer patients whose first- line or subsequent chemotherapy has failed. In addition, it is currently in clinical trials to determine if it is safe and efficacious in treating other tumor types. TAXOL was developed by Bristol-Myers Squibb and the National Cancer Institute under a Cooperative Research and Development Agreement (CRADA).
 The only TAXOL approved for human use is derived from the bark of the Pacific yew tree, Taxus brevifolia, found primarily in the Pacific Northwest. Bristol-Myers Squibb expects to produce significant quantities of TAXOL by semisynthetic means in 1993. Plant cell culture represents a potentially new method of producing paclitaxel commercially. To date, no pharmaceutical products have been made on a commercial scale using plant cell culture techniques. However, this technology is attractive because it affords higher controllability and potentially lower production costs relative to other methods.
 Commenting on the agreement, Dr. Venkat, chairman and chief executive officer of Phyton Catalytic, stated, "This represents the next logical phase of joint development between our companies. Bristol-Myers Squibb's vast experience in microbial fermentations and animal cell culture, coupled with its expertise in commercializing biotechnological products, complements our technical strengths in the effort to establish a commercially viable cell culture process for paclitaxel production."
 Zola Horovitz, vice president - business development and planning of Bristol-Myers Squibb, said, "We are engaged in a massive worldwide effort to establish alternative paclitaxel sources for TAXOL. Phyton Catalytic's plant cell culture technology may become a meaningful source of long-term supply of paclitaxel. In addition, Phyton's technology is attractive to Bristol-Myers Squibb because of its potential in the discovery of other drug candidates, including other taxanes."
 Bristol-Myers Squibb is a diversified, research-based health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices.
 Phyton Catalytic, Inc., based in Ithaca, N.Y., is a biotechnology company focused on the development and supply of high value plant- derived compounds for the pharmaceutical, cosmetic and specialty chemicals industries.
 -0- 8/3/93
 /CONTACT: Dr. Kris Venkat, chairman and chief executive officer of Phyton Catalytic, Inc., 607-257-5058, or fax, 607-257-5515/


CO: Phyton Catalytic, Inc.; Bristol-Myers Squibb Company ST: New York IN: MTC SU:

TM-MP -- NY087 -- 9076 08/03/93 17:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1993
Words:504
Previous Article:ALLEN-BRADLEY DISBANDS ITS INTERNATIONAL GROUP TO CREATE "TRULY GLOBAL" ORGANIZATION; APPOINTS HEAD OF NEW ASIA PACIFIC REGION
Next Article:DUFF & PHELPS REAFFIRMS RATINGS ON SEARS CREDIT ACCOUNT TRUSTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters